Cyclophosphamide: New approaches for systemic lupus erythematosus

Research output: Contribution to journalArticle

Abstract

Cyclophosphamide remains the 'gold standard' treatment for severe organ threatening systemic lupus erythematosus (SLE), especially renal and central nervous system lupus. Intravenous and oral cyclophosphamide have been compared, retrospectively, with similar two year remission rates of 73% and 90%. In a meta-analysis, intravenous cyclophosphamide with oral prednisone is more effective than oral prednisone alone. The efficacy of cyclophosphamide in lupus nephritis has been proven in multiple clinical trials, but efficacy has to be balanced with toxicity, including infection, gonadal failure, and malignancy. Although the continued use of cyclophosphamide for renal lupus has been challenged by a recent trial of mycophenolate mofetil, and may be challenged in the future by planned trials of biologics, it continues to be widely used. This review will touch on the traditional intravenous 'pulse' cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide.

Original languageEnglish (US)
Pages (from-to)366-371
Number of pages6
JournalLupus
Volume13
Issue number5
DOIs
StatePublished - 2004

Fingerprint

Systemic Lupus Erythematosus
Cyclophosphamide
Prednisone
Central Nervous System Lupus Vasculitis
Mycophenolic Acid
Kidney
Lupus Nephritis
Biological Products
Meta-Analysis
Clinical Trials
Infection
Neoplasms

Keywords

  • Cyclophosphamide
  • SLE

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Cyclophosphamide : New approaches for systemic lupus erythematosus. / Petri, Michelle.

In: Lupus, Vol. 13, No. 5, 2004, p. 366-371.

Research output: Contribution to journalArticle

@article{54bac5f6f3704148a8563084abcfbd69,
title = "Cyclophosphamide: New approaches for systemic lupus erythematosus",
abstract = "Cyclophosphamide remains the 'gold standard' treatment for severe organ threatening systemic lupus erythematosus (SLE), especially renal and central nervous system lupus. Intravenous and oral cyclophosphamide have been compared, retrospectively, with similar two year remission rates of 73{\%} and 90{\%}. In a meta-analysis, intravenous cyclophosphamide with oral prednisone is more effective than oral prednisone alone. The efficacy of cyclophosphamide in lupus nephritis has been proven in multiple clinical trials, but efficacy has to be balanced with toxicity, including infection, gonadal failure, and malignancy. Although the continued use of cyclophosphamide for renal lupus has been challenged by a recent trial of mycophenolate mofetil, and may be challenged in the future by planned trials of biologics, it continues to be widely used. This review will touch on the traditional intravenous 'pulse' cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide.",
keywords = "Cyclophosphamide, SLE",
author = "Michelle Petri",
year = "2004",
doi = "10.1191/0961203303lu1028oa",
language = "English (US)",
volume = "13",
pages = "366--371",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Cyclophosphamide

T2 - New approaches for systemic lupus erythematosus

AU - Petri, Michelle

PY - 2004

Y1 - 2004

N2 - Cyclophosphamide remains the 'gold standard' treatment for severe organ threatening systemic lupus erythematosus (SLE), especially renal and central nervous system lupus. Intravenous and oral cyclophosphamide have been compared, retrospectively, with similar two year remission rates of 73% and 90%. In a meta-analysis, intravenous cyclophosphamide with oral prednisone is more effective than oral prednisone alone. The efficacy of cyclophosphamide in lupus nephritis has been proven in multiple clinical trials, but efficacy has to be balanced with toxicity, including infection, gonadal failure, and malignancy. Although the continued use of cyclophosphamide for renal lupus has been challenged by a recent trial of mycophenolate mofetil, and may be challenged in the future by planned trials of biologics, it continues to be widely used. This review will touch on the traditional intravenous 'pulse' cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide.

AB - Cyclophosphamide remains the 'gold standard' treatment for severe organ threatening systemic lupus erythematosus (SLE), especially renal and central nervous system lupus. Intravenous and oral cyclophosphamide have been compared, retrospectively, with similar two year remission rates of 73% and 90%. In a meta-analysis, intravenous cyclophosphamide with oral prednisone is more effective than oral prednisone alone. The efficacy of cyclophosphamide in lupus nephritis has been proven in multiple clinical trials, but efficacy has to be balanced with toxicity, including infection, gonadal failure, and malignancy. Although the continued use of cyclophosphamide for renal lupus has been challenged by a recent trial of mycophenolate mofetil, and may be challenged in the future by planned trials of biologics, it continues to be widely used. This review will touch on the traditional intravenous 'pulse' cyclophosphamide regimen, consider its toxicity, and contrast it with newer approaches to cyclophosphamide.

KW - Cyclophosphamide

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=2942754017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942754017&partnerID=8YFLogxK

U2 - 10.1191/0961203303lu1028oa

DO - 10.1191/0961203303lu1028oa

M3 - Article

C2 - 15230294

AN - SCOPUS:2942754017

VL - 13

SP - 366

EP - 371

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 5

ER -